Recent investigations have centered on the intersection of GLP|GIP|glucagon receptor activator therapies and DA communication. While GLP stimulators are increasingly employed for managing type 2 diabetes mellitus, their potential effects on motivation circuits, specifically mediated by dopamine networks, are attracting considerable focus. This repo